Abstract Details

Title Metastatic Glioblastoma to the Lungs

Topic Neuro-oncology

Presentation(s) P3 - Poster Session 3 (11:45 AM-12:45 PM)

Poster/Presentation
Number 6-018

Objective We present a case of a 63-year-old woman with metastatic glioblastoma in the lungs. We examine possible risk factors, including genomic alterations, for the development of her extra-neural disease. We also describe her treatment response to lenvatinib monotherapy.

Background Glioblastoma is the most commonly occurring malignant primary brain tumor []. Despite the infiltrative nature of glioblastoma, metastases are infrequent with an incidence of only 0.4–2.0%. Accordingly, the rare detection of metastases has resulted in the forgoing of staging for glioblastoma. However, cases are on the rise due to heightened awareness and evidence suggests that 20% of glioblastoma cases are found to have tumor-circulating cells. Despite this finding, glioblastoma predominantly remains an intracranial disease.

For the subset of cases in which metastases do occur, extra-cranial intra-neural drop metastases to the spine are more common than extra-neural dissemination to outside organs. Prognosis remains especially poor with a median overall survival of 10.5 months.

Design/Methods We present a case of a 63-year-old woman with metastatic glioblastoma in the lungs. Sarcomatous histology, a reported risk factor for disseminated disease, was found. Genomic alterations of TP53 mutation, TERT mutation, PTEN mutation, and +7/-10 were also uncovered. Early evidence suggests these molecular aberrations are common in metastatic glioblastoma.

Results

A dramatic response was observed in her intracranial tumor. Her systemic lung disease did not demonstrate a response to lenvatinib.

Conclusions Though rare, extra-neural metastases should be considered in the differential of a glioblastoma patient with new systemic symptoms. Early evidence gleaned from metastatic glioblastoma case studies suggests that genomic alterations may play a role in predicting risk for metastatic glioblastoma. Treatment options are needed for metastatic glioblastoma and novel therapies should be investigated.

Authors/Disclosures
Carlen A. Yuen, MD (University of California, Irvine) PRESENTER	Dr. Yuen has nothing to disclose.
Melike Pekmezci, MD	Dr. Pekmezci has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Elsevier.
Silin Bao, NP	Miss Bao has nothing to disclose.
Xiao-Tang Kong, MD, PhD (UC Irvine)	Dr. Kong has nothing to disclose.

��ɫ��

��ɫ��